We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 20% above its sector, the market expects faster growth.
This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6712.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
